SCHEDULE 13G/A: Rosalind Entities Disclose 6.1% Stake in MediWound Ltd. via Amended SEC Filing

Rosalind Advisors, Inc., along with affiliated entities and individuals, has filed an amended Schedule 13G disclosing a 6.1% beneficial ownership stake in MediWound Ltd., totaling 670,158 common shares.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively reported beneficial ownership of 670,158 common shares of MediWound Ltd.
• This represents 6.1% of MediWound Ltd.'s common stock outstanding.
• The ownership is comprised of 506,893 common shares and 163,265 shares issuable upon the exercise of warrants.
• The percentage is calculated based on 10,793,057 shares of MediWound's common stock outstanding as of December 31, 2024, as reported in the company's 20F filing on March 19, 2025.
• A blocker provision exists for the warrants, preventing exercise if it would result in beneficial ownership exceeding 9.99% of the Common Stock.
• Rosalind Advisors, Inc. acts as the investment advisor to Rosalind Master Fund L.P.
• Steven Salamon is the President of Rosalind Advisors, Inc. and portfolio manager, while Gilad Aharon is also a portfolio manager and member of the Advisor.
• All reporting persons disclaim beneficial ownership of the shares, except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing itself is a routine disclosure of ownership. The continued significant stake by an institutional investor can be seen as a minor positive signal of confidence, but it's not an operational or financial performance report.

Positives

• A significant institutional investor, Rosalind Advisors, Inc. and its affiliates, maintains a substantial stake in MediWound Ltd., indicating continued interest.

Risks

• The warrant shares are subject to a 'blocker provision' which prevents exercise if it would result in beneficial ownership exceeding 9.99% of the Common Stock, potentially limiting the immediate conversion of all warrant-held shares.

Future Outlook

NA

Management Comments

• "Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF."
• "Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF."
• "Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a standard disclosure of significant beneficial ownership by an institutional investor in a biotechnology or pharmaceutical company (MediWound Ltd. is a biopharmaceutical company). Such filings indicate an investor's position but do not typically provide broader industry analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.

Key Dates

Keywords

MediWound Ltd., Rosalind Advisors, Schedule 13G, Beneficial Ownership, Common Shares, Warrants, Institutional Investor, SEC Filing, M68830104